Scienture Holdings, Inc. (NASDAQ:SCNX) Short Interest Down 29.7% in January

Scienture Holdings, Inc. (NASDAQ:SCNX) saw a significant drop in short interest in January. As of January 30th, there was short interest totaling 2,463,891 shares, a drop of 29.7% from the January 15th total of 3,504,653 shares. Based on an average daily trading volume, of 681,002 shares, the days-to-cover ratio is currently 3.6 days. Approximately 7.7% of the shares of the company are sold short. Approximately 7.7% of the shares of the company are sold short. Based on an average daily trading volume, of 681,002 shares, the days-to-cover ratio is currently 3.6 days.

Scienture Stock Performance

NASDAQ:SCNX opened at $0.43 on Friday. The company has a market cap of $17.59 million, a price-to-earnings ratio of -0.43 and a beta of 3.02. Scienture has a fifty-two week low of $0.42 and a fifty-two week high of $3.61. The stock has a fifty day moving average price of $0.52 and a 200-day moving average price of $0.83.

Scienture (NASDAQ:SCNX) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.19) EPS for the quarter. The company had revenue of $0.59 million during the quarter.

Hedge Funds Weigh In On Scienture

A hedge fund recently raised its stake in Scienture stock. Geode Capital Management LLC lifted its position in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) by 264.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 316,201 shares of the company’s stock after acquiring an additional 229,398 shares during the period. Geode Capital Management LLC owned approximately 0.78% of Scienture worth $161,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 5.68% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on SCNX. Wall Street Zen lowered shares of Scienture from a “hold” rating to a “sell” rating in a research report on Sunday, January 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Scienture in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Scienture has a consensus rating of “Sell”.

Scienture Company Profile

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.